Cargando…

Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes

BACKGROUND: We report prospectively captured clinical toxicity and patient reported outcomes in a single institutional cohort of patients treated for prostate cancer with proton beam therapy (PBT). This is the largest reported series of patients treated mostly with pencil beam scanning PBT. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Howard J., Macomber, Meghan W., Spraker, Matthew B., Bowen, Stephen R., Hippe, Daniel S., Fung, Angela, Russell, Kenneth J., Laramore, George E., Rengan, Ramesh, Liao, Jay, Apisarnthanarax, Smith, Zeng, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142310/
https://www.ncbi.nlm.nih.gov/pubmed/30223877
http://dx.doi.org/10.1186/s13014-018-1127-6
_version_ 1783355831048208384
author Lee, Howard J.
Macomber, Meghan W.
Spraker, Matthew B.
Bowen, Stephen R.
Hippe, Daniel S.
Fung, Angela
Russell, Kenneth J.
Laramore, George E.
Rengan, Ramesh
Liao, Jay
Apisarnthanarax, Smith
Zeng, Jing
author_facet Lee, Howard J.
Macomber, Meghan W.
Spraker, Matthew B.
Bowen, Stephen R.
Hippe, Daniel S.
Fung, Angela
Russell, Kenneth J.
Laramore, George E.
Rengan, Ramesh
Liao, Jay
Apisarnthanarax, Smith
Zeng, Jing
author_sort Lee, Howard J.
collection PubMed
description BACKGROUND: We report prospectively captured clinical toxicity and patient reported outcomes in a single institutional cohort of patients treated for prostate cancer with proton beam therapy (PBT). This is the largest reported series of patients treated mostly with pencil beam scanning PBT. METHODS: We reviewed 231 patients treated on an IRB approved institutional registry from 2013 to 2016; final analysis included 192 patients with > 1-year of follow-up. Toxicity incidence was prospectively captured and scored using CTCAE v4.0. International Prostate Symptoms Score (IPSS), Sexual Health Inventory for Men (SHIM) score, and Expanded Prostate Cancer Index Composite (EPIC) bowel domain questionnaires were collected at each visit. Univariate Cox regression was used to explore associations of grade 2+ toxicity with clinical, treatment, and dosimetric variables. RESULTS: Median follow-up was 1.7 years. Grade 3 toxicity was seen in 5/192 patients. No grade 4 or 5 toxicity was seen. Patient reported quality-of-life showed no change in urinary function post-radiation by IPSS scores. Median SHIM scores declined by 3.7 points at 1-year post-treatment without further decrease beyond year 1. On univariate analysis, only younger age (HR = 0.61, p = 0.022) was associated with decreased sexual toxicity. EPIC bowel domain scores declined from 96 at baseline (median) by an average of 5.4 points at 1-year post-treatment (95% CI: 2.5–8.2 points, p < 0.001), with no further decrease over time. Bowel toxicity was mostly in the form of transient rectal bleeding and was associated with anticoagulation use (HR = 3.45, p = 0.002). CONCLUSIONS: Grade 3 or higher toxicity was rare at 2-years after treatment with PBT for localized prostate cancer. Longer follow-up is needed to further characterize late toxicity and biochemical control. TRIAL REGISTRATION: NCT, NCT01255748. Registered 1 January 2013.
format Online
Article
Text
id pubmed-6142310
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-61423102018-09-20 Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes Lee, Howard J. Macomber, Meghan W. Spraker, Matthew B. Bowen, Stephen R. Hippe, Daniel S. Fung, Angela Russell, Kenneth J. Laramore, George E. Rengan, Ramesh Liao, Jay Apisarnthanarax, Smith Zeng, Jing Radiat Oncol Research BACKGROUND: We report prospectively captured clinical toxicity and patient reported outcomes in a single institutional cohort of patients treated for prostate cancer with proton beam therapy (PBT). This is the largest reported series of patients treated mostly with pencil beam scanning PBT. METHODS: We reviewed 231 patients treated on an IRB approved institutional registry from 2013 to 2016; final analysis included 192 patients with > 1-year of follow-up. Toxicity incidence was prospectively captured and scored using CTCAE v4.0. International Prostate Symptoms Score (IPSS), Sexual Health Inventory for Men (SHIM) score, and Expanded Prostate Cancer Index Composite (EPIC) bowel domain questionnaires were collected at each visit. Univariate Cox regression was used to explore associations of grade 2+ toxicity with clinical, treatment, and dosimetric variables. RESULTS: Median follow-up was 1.7 years. Grade 3 toxicity was seen in 5/192 patients. No grade 4 or 5 toxicity was seen. Patient reported quality-of-life showed no change in urinary function post-radiation by IPSS scores. Median SHIM scores declined by 3.7 points at 1-year post-treatment without further decrease beyond year 1. On univariate analysis, only younger age (HR = 0.61, p = 0.022) was associated with decreased sexual toxicity. EPIC bowel domain scores declined from 96 at baseline (median) by an average of 5.4 points at 1-year post-treatment (95% CI: 2.5–8.2 points, p < 0.001), with no further decrease over time. Bowel toxicity was mostly in the form of transient rectal bleeding and was associated with anticoagulation use (HR = 3.45, p = 0.002). CONCLUSIONS: Grade 3 or higher toxicity was rare at 2-years after treatment with PBT for localized prostate cancer. Longer follow-up is needed to further characterize late toxicity and biochemical control. TRIAL REGISTRATION: NCT, NCT01255748. Registered 1 January 2013. BioMed Central 2018-09-17 /pmc/articles/PMC6142310/ /pubmed/30223877 http://dx.doi.org/10.1186/s13014-018-1127-6 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Lee, Howard J.
Macomber, Meghan W.
Spraker, Matthew B.
Bowen, Stephen R.
Hippe, Daniel S.
Fung, Angela
Russell, Kenneth J.
Laramore, George E.
Rengan, Ramesh
Liao, Jay
Apisarnthanarax, Smith
Zeng, Jing
Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes
title Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes
title_full Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes
title_fullStr Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes
title_full_unstemmed Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes
title_short Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes
title_sort early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142310/
https://www.ncbi.nlm.nih.gov/pubmed/30223877
http://dx.doi.org/10.1186/s13014-018-1127-6
work_keys_str_mv AT leehowardj earlytoxicityandpatientreportedqualityoflifeinpatientsreceivingprotontherapyforlocalizedprostatecancerasingleinstitutionalreviewofprospectivelyrecordedoutcomes
AT macombermeghanw earlytoxicityandpatientreportedqualityoflifeinpatientsreceivingprotontherapyforlocalizedprostatecancerasingleinstitutionalreviewofprospectivelyrecordedoutcomes
AT sprakermatthewb earlytoxicityandpatientreportedqualityoflifeinpatientsreceivingprotontherapyforlocalizedprostatecancerasingleinstitutionalreviewofprospectivelyrecordedoutcomes
AT bowenstephenr earlytoxicityandpatientreportedqualityoflifeinpatientsreceivingprotontherapyforlocalizedprostatecancerasingleinstitutionalreviewofprospectivelyrecordedoutcomes
AT hippedaniels earlytoxicityandpatientreportedqualityoflifeinpatientsreceivingprotontherapyforlocalizedprostatecancerasingleinstitutionalreviewofprospectivelyrecordedoutcomes
AT fungangela earlytoxicityandpatientreportedqualityoflifeinpatientsreceivingprotontherapyforlocalizedprostatecancerasingleinstitutionalreviewofprospectivelyrecordedoutcomes
AT russellkennethj earlytoxicityandpatientreportedqualityoflifeinpatientsreceivingprotontherapyforlocalizedprostatecancerasingleinstitutionalreviewofprospectivelyrecordedoutcomes
AT laramoregeorgee earlytoxicityandpatientreportedqualityoflifeinpatientsreceivingprotontherapyforlocalizedprostatecancerasingleinstitutionalreviewofprospectivelyrecordedoutcomes
AT renganramesh earlytoxicityandpatientreportedqualityoflifeinpatientsreceivingprotontherapyforlocalizedprostatecancerasingleinstitutionalreviewofprospectivelyrecordedoutcomes
AT liaojay earlytoxicityandpatientreportedqualityoflifeinpatientsreceivingprotontherapyforlocalizedprostatecancerasingleinstitutionalreviewofprospectivelyrecordedoutcomes
AT apisarnthanaraxsmith earlytoxicityandpatientreportedqualityoflifeinpatientsreceivingprotontherapyforlocalizedprostatecancerasingleinstitutionalreviewofprospectivelyrecordedoutcomes
AT zengjing earlytoxicityandpatientreportedqualityoflifeinpatientsreceivingprotontherapyforlocalizedprostatecancerasingleinstitutionalreviewofprospectivelyrecordedoutcomes